Articles tagged with Colon Cancer
A new poll found that 62% of people aged 50-80 disagree with using life expectancy as a factor in determining cancer screening guidelines. The majority also believes that some older adults should still receive cancer screenings even if guidelines don't recommend them.
A Rice University-led team of researchers has been awarded $45 million to develop a new sense-and-respond implant technology that could improve immunotherapy outcomes for patients with difficult-to-treat cancers. The technology, called THOR, aims to provide real-time data from the tumor environment to guide more effective therapies.
Researchers have identified new genetic markers to detect Lynch syndrome-associated colorectal cancer with 92% accuracy. The discovery could lead to a non-invasive screening option using stool samples, reducing the need for annual colonoscopies and invasive tests.
New research from Cold Spring Harbor Laboratory suggests that high tumor mutation burden does not guarantee an effective immune response in patients with mismatch repair deficiency. The study found that tumors with identical mutations across all cells responded to immunotherapy, while those with subclonal mutations did not.
Researchers have characterised a specialised type of immune cell that plays a key role in protecting and repairing the healthy human gut. Depletion of these cells is linked to inflammatory bowel disease (IBD) progression, with potential implications for treatment options.
A team of scientists at VCU Massey Cancer Center discovered a previously unknown interaction between proteins that supplies energy to tumor cells, holding significant implications for colon cancer treatments. By blocking heat shock protein 27 activity, researchers confirmed a decrease in mitochondrial function and death of cancer cells.
Mayo Clinic researchers found that cells expressing PD-1 and PD-L1 within a certain distance of each other can predict the success of immunotherapy in patients with colorectal cancer. This spatial analysis may help select patients most likely to benefit from treatment, improving outcomes and minimizing unnecessary treatments.
Researchers found that mutations in blood stem cells can promote the development of colitis-associated colon cancer (CAC) by increasing blood vessel formation. Blocking certain drugs, such as axitinib, inhibited CAC tumor growth in mice with clonal hematopoiesis, suggesting potential therapeutic strategies.
Researchers used base editors to introduce specific combinations of activating and inactivating mutations into healthy organoids, creating realistic models for various types of cancer. This allows for further investigation into the development and treatment of cancer, with potential applications including testing new drugs.
A new study estimates that cancer screenings have saved the US at least $6.5 trillion and led to 12 million more years of life, with significant economic impact from breast, colon, cervical, and lung cancer screenings.
A large long-term study found that good cardiorespiratory fitness in young men is associated with a significantly lower risk of developing nine specific cancers, including a 40% reduced risk of liver cancer. Higher fitness was also linked to lower risks of rectal, pancreatic, and bowel cancers.
Researchers have engineered bacteria that can detect tumor DNA in a live organism, using CRISPR technology. The bacteria, Acinetobacter baylyi, were designed to respond to specific DNA sequences associated with cancer, allowing for early detection and potentially preventing disease progression.
A new study published in JNCCN found that the adoption of clinical research results led to a significant increase in the use of shorter adjuvant chemotherapy periods, with CAPOX becoming more widely used. The study also revealed disparities in treatment patterns, with Black patients being more likely to receive shorter chemotherapy reg...
A new study found that 81% of women report persistent GI symptoms years after diagnosis, with abdominal bloating and gas being the most common. The analysis also showed that severe GI symptoms are linked to poor quality of life, social activities, and body image satisfaction.
Researchers found that expression of transcription factors contributes to different subtypes of colorectal cancers. The degree of DNA methylation varies across tissue types, with some cancers having high and others low frequency of methylation gains. Studying transcription factor expression may help determine overall survival in patien...
A new study reveals that the cellular chaperone protein GRP78 migrates to the nucleus under stress and alters gene activities, allowing cancer cells to become more mobile and invasive. This discovery offers potential new approaches for cancer treatment, including down-regulating GRP78 activity or preventing it from binding to ID2.
Researchers identified a new mechanism by which cancer hijacks enzyme substrate motif mutations, enabling tumor growth and therapy resistance. The study found that colorectal cancer hijacks BUD13 mutations to inactivate a key tumor suppressor, Fbw7.
A collaborative study by researchers at the University of Ottawa and McMaster University has made a groundbreaking discovery linking different types of cancers to their embryonic origins. The team found that drugs targeting specific embryonic pathways can effectively treat various tumors, including brain, colon, and leukemia cancers.
A study by Regenstrief Institute has identified seven risk factors for early onset colorectal cancer in males, providing a framework for clinicians to consider screening recommendations for younger men. The model may help estimate relative risk and identify individuals at higher risk for colorectal cancer.
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
The study investigates the effects of DPDT on human colon cancer HCT116 cells and non-tumorigenic MRC5 fibroblasts. The results show that DPDT preferentially targets HCT116 cells, inducing apoptosis and G2/M cell cycle arrest, likely through DNA topoisomerase I poisoning.
Researchers have discovered abnormalities in the DNA instruction code that lead to the aggressive spread of colorectal cancer. By studying DNA methylation levels, they identified unique gene regions associated with liver metastasis and found a link between these changes and cancer cell aggression.
A new study published in the Journal of the American College of Surgeons found that people who live in historically redlined areas are less likely to be screened for breast, colorectal, and cervical cancer. The legacy of redlining continues to contribute to significant disparities in cancer screening rates.
Researchers found specific bacterial species significantly associated with the development of tubular adenomas and sessile serrated adenomas. The study suggests a potential opportunity to intervene through diet or probiotics to prevent colorectal cancer.
Researchers found that MALAT1 inhibition decreased BRAF RNA and protein levels, while increasing correlation with MAPK-associated genes. MALAT1-ASO treatment also reduced melanoma cell growth and tumor size in xenograft models.
Research reveals both metabolically healthy and unhealthy obesity types linked to increased risk of various obesity-related cancers, with stronger association in metabolically unhealthy obesity. Metabolically unhealthy women face higher risks for endometrial, liver, and kidney cancers.
A new study found that being overweight or obese during early and middle adulthood increases the risk of gastrointestinal cancers in later life. The research also suggests that frequent aspirin use does not modify this increased risk.
Researchers have highlighted the importance of stromal vitamin A pathway in regulating IL-6 expression in colorectal cancer-associated fibroblasts. The study found that disrupting retinol-mediated IL-6 expression could be a potential approach to target CAFs during CRC treatment.
A recent study led by Dr Rachael Rigby from Lancaster University found that delays in stoma reversal surgery do not impact on risk of complications or commensal microflora loss, atrophy, or scarring. However, a higher degree of microflora loss is associated with an increased risk of complications.
Scientists have created a new method to model liver cancer tumor subtypes using CRISPR-Cas9, discovering that specific gene isoforms can lead to different cancer subtypes. This platform could help researchers develop new therapeutic interventions for treating cancer and other diseases.
Researchers propose a new method of clustering colorectal cancer patients using differential presence of exons (DPE) sequencing, which can provide valuable information on CRC progression and response to therapy. This analysis may also reduce costs and time required for staging CRC patients.
A UNIGE team created customizable treatments by testing drugs on artificial tumors derived from patients' cancer tissue. The approach opens the way for optimized and tailored therapies against various cancers and diseases.
A new study of over 200 people with premature aging syndromes caused by abnormally short telomeres suggests that chromosomal instability may not be the reason for increased cancer risk. Instead, immune system cells that age and die prematurely may play a role in cancer predisposition.
Researchers propose conjugating a cell-penetrating peptide to oxaliplatin to overcome chemotherapy resistance in colorectal cancer. The new approach reduces platinum accumulation in tumour microenvironment and healthy tissues.
Researchers found that cells in the colon undergo a type of molecular time travel, reverting back to an embryonic state and creating immature, non-functional cells that can form benign growths called adenomas. Blocking Sox9 in mouse models prevented adenoma formation and resulted in mature cell maturation.
Scientists have engineered a unique strain of probiotic bacteria to over-express a metal transporter that binds and concentrates copper, facilitating the delivery of radionuclide therapy to cancer cells. This approach targets tumors without relying on specific receptors, making it potentially effective against treatment-resistant cancers.
Researchers found that physical activity can prevent cancer recurrence in stage III colon cancer patients by lowering the recurrence rate within the first year of treatment. This association persisted for approximately three years after surgery, suggesting a long-term survival benefit.
Researchers found that a combination of symptom and high-level viral rebound after untreated COVID-19 infection is rare, occurring in only 3 percent of study participants. This suggests that accounting for underlying rates of symptom relapse is crucial when evaluating antiviral treatment effects.
Researchers discovered that combining ferroptosis induction with immune checkpoint inhibition reduces liver tumour growth and metastases, offering a promising new approach for treating liver cancer
Researchers at Ruhr University Bochum developed a new digital imaging method using artificial intelligence and infrared imaging to determine microsatellite status in colon cancer. This approach enables fast, label-free, and automated detection of the biomarker, which is crucial for personalized medicine.
A Cancer Research UK-funded clinical trial found that chemotherapy before surgery reduces the chance of colon cancer returning within 2 years by 28%. The study involved 1,053 patients and showed significant benefits in terms of preventing cancer recurrence.
A new study finds that exposure to salmonella bacteria increases colon cancer risk, with tumors developing earlier and growing larger in infected mice. The research highlights the potential for salmonella as an environmental risk factor for chronic diseases like colon cancer.
This study found that advanced colorectal neoplasia prevalence is low 10 or more years after a negative screening colonoscopy. Extended screening intervals may be recommended for female and younger participants without gastrointestinal symptoms.
A new study found that multiple negative faecal immunochemical tests can significantly reduce the risk of advanced neoplasia in a colonoscopy surveillance program. This could lead to longer intervals between screenings for people at above-average risk, reducing the burden on healthcare systems.
Researchers discovered that pre-surgery immunotherapy significantly improved patient outcomes for locally advanced colorectal cancer. The treatment showed substantial longer survival benefits, including low recurrence rates, in patients with mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) CRC.
Research from Michigan Medicine reveals that high levels of ammonia in colon tumors can lead to reduced T cell growth and immunotherapy resistance. A study published in Cell Metabolism found that using an FDA-approved drug to lower ammonia levels made tumors more sensitive to treatment.
A massive international data analysis uncovered hundreds of signals for new treatment and prevention targets in colorectal cancer. The study identified 250 independent risk associations, including 50 newly discovered ones, through analyzing genomic, transcriptomic, and methylomic data.
Researchers discovered PDGF cross-signaling through alternative receptors in colorectal cancer cells, enabling bypassed signaling. This finding supports anti-PDGF therapy as a combination strategy alongside VEGF and EGF targeting.
A study found that concerns about colonoscopy, lack of opportunity to discuss next steps with a medical provider, and assumptions about personal risk are common reasons patients don't follow up after a positive at-home test. Researchers also developed two simple risk measurement tools to predict COVID-19 mortality rates, which could he...
A nationwide questionnaire in Dutch colorectal cancer screening found that concerns about colonoscopy, lack of provider discussion, and personal risk perceptions are common reasons for not following up. Personalized screening counseling and family practitioner involvement may help increase follow-up rates.
Researchers at University of Pittsburgh have designed novel nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy, shrinking tumors in mouse models of colon and pancreatic cancer. The therapy silences a gene involved in immunosuppression by blocking Xkr8 protein distribution on the cell membrane.
A low-protein diet blocks nutrient signaling pathways that fire up a master regulator of cancer growth, leading to massive cell death. Researchers found this approach could be an alternative way to shut down mTORC and increase the efficacy of chemotherapy.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
Researchers at Goethe University Frankfurt found that dying colon cancer cells release ATP to neighboring tumor cells, activating a survival signaling pathway. Interrupting this communication can significantly increase the effectiveness of chemotherapy against resistant tumors.
Researchers found that a new drug inhibiting GRP78 effectively reduces SARS-CoV-2 replication in human lung cells. The drug also shows potential in treating certain types of cancer by suppressing mutant KRAS proteins.
Researchers have discovered that targeting a specific mutation in fibrolamellar tumors can reduce tumor growth in mice, offering a promising approach to treating this nearly incurable cancer. The findings highlight the potential for novel therapies against an intractable disease.
Researchers at IRB Barcelona have identified the tiny fraction of tumour cells that remain hidden after surgery, leading to metastatic recurrence. These 'High Relapse Cells' can be eliminated through genetic techniques, preventing metastases and opening the possibility for new therapeutic strategies.
Researchers at UNIGE have discovered a way to overcome resistance to chemotherapy in colorectal cancer, using an optimized combination of tyrosine kinase inhibitors. This breakthrough opens up new avenues for developing targeted therapies that can effectively treat patients with low five-year survival rates.
In a patient trial, the AKT inhibitor ipatasertib showed signs of effectiveness in treating advanced cancers. 22% of patients experienced tumor shrinkage, while 56% had stable disease. Further research is needed to understand why some patients responded and others did not.
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.